文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

危重型COVID-19急性肾损伤时磁共振成像评估肾灌注降低:一项前瞻性病例对照研究

Decreased renal perfusion during acute kidney injury in critical COVID-19 assessed by magnetic resonance imaging: a prospective case control study.
PubMed 文献 · Crit Care · 2022-09-01
一句话结论危重型COVID-19合并AKI患者的总肾血流量、皮质和髓质灌注较无AKI者降低,但肾氧合无差异。

这项前瞻性病例对照研究纳入19例因COVID-19呼吸衰竭入住ICU且既往无肾病的患者,按KDIGO肌酐标准分为AKI组10例与无AKI组9例。AKI组在中位1[0-2]天达标后行多参数MRI检查。AKI组总肾血流量中位数645[423-753]ml/min,低于无AKI组的859[746-920]ml/min(p=0.037);皮质灌注76[51-112] vs 146[123-169]ml/100g/min(p=0.015),髓质灌注28[18-47] vs 47[38-73]ml/100g/min(p=0.03)。肾静脉血氧饱和度及皮质、髓质R2*两组无显著差异。提示危重型COVID-19合并AKI存在肾低灌注,但未显示氧合差异。

要点

  • 危重型COVID-19合并AKI患者总肾血流量中位数645[423-753]ml/min,低于无AKI患者的859[746-920]ml/min(p=0.037)。
  • AKI组皮质灌注中位数76[51-112]ml/100g/min,低于无AKI组的146[123-169]ml/100g/min(p=0.015)。
  • AKI组髓质灌注中位数28[18-47]ml/100g/min,低于无AKI组的47[38-73]ml/100g/min(p=0.03)。
  • 两组肾静脉血氧饱和度均为72%(AKI组72%[64-75] vs 无AKI组72%[63-84],无显著差异)。
  • 皮质R2*(17[16-19] vs 17[16-18] 1/s)和髓质R2*(29[24-39] vs 27[23-29] 1/s)两组无显著差异。

适用人群与场景

  • 因COVID-19呼吸衰竭入住ICU、既往无肾病的危重症患者;AKI组10例,无AKI组9例。

诊断标准与关键阈值

  • 采用改善全球肾脏病预后组织(KDIGO)肌酐标准进行分组。
  • AKI组在中位1[0-2]天(达到KDIGO肌酐标准后)接受多参数MRI检查。

研究设计与关键结果

  • 研究类型:前瞻性病例对照研究;样本量19例(AKI组10例,无AKI组9例);人群:因COVID-19呼吸衰竭入住ICU且既往无肾病的危重症患者。
  • 主要比较采用Mann-Whitney U检验。
  • 总肾血流量:AKI组中位数645[423-753]ml/min vs 无AKI组859[746-920]ml/min,p=0.037。
  • 皮质灌注:AKI组76[51-112]ml/100g/min vs 无AKI组146[123-169]ml/100g/min,p=0.015。
  • 髓质灌注:AKI组28[18-47]ml/100g/min vs 无AKI组47[38-73]ml/100g/min,p=0.03。
  • 肾静脉血氧饱和度:AKI组72%[64-75] vs 无AKI组72%[63-84],无显著差异。
  • 皮质R2*:AKI组17[16-19]1/s vs 无AKI组17[16-18]1/s,无显著差异;髓质R2*:AKI组29[24-39]1/s vs 无AKI组27[23-29]1/s,无显著差异。
  • 年龄与基线血浆肌酐两组相似。

证据类型、等级与局限

  • 证据类型:前瞻性病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在危重型COVID-19合并AKI患者中,总肾血流量、皮质和髓质灌注较无AKI的类似患者降低,而肾氧合未见差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Renal hypoperfusion has been suggested to contribute to the development of acute kidney injury (AKI) in critical COVID-19. However, limited data exist to support this. We aim to investigate the differences in renal perfusion, oxygenation and water diffusion using multiparametric magnetic resonance imaging in critically ill COVID-19 patients with and without AKI.

METHODS: A prospective case-control study where patients without prior kidney disease treated in intensive care for respiratory failure due to COVID-19 were examined. Kidney Disease: Improving Global Outcomes Creatinine criteria were used for group allocation. Main comparisons were tested using Mann-Whitney U test.

RESULTS: Nineteen patients were examined, ten with AKI and nine without AKI. Patients with AKI were examined in median 1 [0-2] day after criteria fulfillment. Age and baseline Plasma-Creatinine were similar in both groups. Total renal blood flow was lower in patients with AKI compared with patients without (median 645 quartile range [423-753] vs. 859 [746-920] ml/min, p = 0.037). Regional perfusion was reduced in both cortex (76 [51-112] vs. 146 [123-169] ml/100 g/min, p = 0.015) and medulla (28 [18-47] vs. 47 [38-73] ml/100 g/min, p = 0.03). Renal venous saturation was similar in both groups (72% [64-75] vs. 72% [63-84], ns.), as was regional oxygenation (R2*) in cortex (17 [16-19] vs. 17 [16-18] 1/s, ns.) and medulla (29 [24-39] vs. 27 [23-29] 1/s, ns.).

CONCLUSIONS: In critically ill COVID-19 patients with AKI, the total, cortical and medullary renal blood flows were reduced compared with similar patients without AKI, whereas no differences in renal oxygenation were demonstrable in this setting. Trial registration ClinicalTrials ID: NCT02765191 , registered May 6 2014 and updated May 7 2020.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Luther T, Eckerbom P, Cox E, et al. Decreased renal perfusion during acute kidney injury in critical COVID-19 assessed by magnetic resonance imaging: a prospective case control study. Crit Care. 2022. PMID: 36050748. doi:10.1186/s13054-022-04132-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。